6:05 PM
 | 
Nov 06, 2012
 |  BC Extra  |  Company News

T-DM1 gets Priority Review

FDA accepted and granted Priority Review to a BLA from Genentech Inc. for trastuzumab emtansine ( T-DM1) to treat HER2-positive, unresectable locally advanced or metastatic breast cancer in patients who have received...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >